Coherus Oncology, Inc. (CHRS) Gross Margin
- Gross margin · 12 months: Value 95.20%; Formula and calculation Gross profit / revenue. Period ending 2019-12-31..
Gross margin
Overview →Financial period ending 2019-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 95.20% | Gross profit / revenue. Period ending 2019-12-31. $338.99M ÷ $356.07M × 100 ≈ 95.20% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 338.99M USD | Gross Profit |
| Revenue | 356.07M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2019-12-31 | $338.99M | $356.07M | (m) | 95.20% |
| 2019-09-30 | (m) | $232.22M | (m) | (m) |
| 2019-06-30 | (m) | $120.53M | (m) | (m) |
| 2019-03-31 | (m) | $37.10M | (m) | (m) |
| 2018-12-31 | (m) | $0.00 | (m) | (m) |
| 2018-09-30 | (m) | $0.00 | (m) | (m) |
| 2018-06-30 | (m) | $0.00 | (m) | (m) |
| 2018-03-31 | (m) | $1.40M | (m) | (m) |
| 2017-12-31 | (m) | $1.56M | (m) | (m) |
| 2017-09-30 | (m) | $2.40M | (m) | (m) |
| 2017-06-30 | (m) | $165.24M | (m) | (m) |
| 2017-03-31 | (m) | $177.91M | (m) | (m) |
| 2016-12-31 | (m) | $190.11M | (m) | (m) |
| 2016-09-30 | (m) | $199.46M | (m) | (m) |
| 2016-06-30 | (m) | $43.79M | (m) | (m) |
| 2016-03-31 | (m) | $36.59M | (m) | (m) |
| 2015-12-31 | (m) | $30.04M | (m) | (m) |
| 2015-09-30 | (m) | $26.34M | (m) | (m) |
| 2015-06-30 | (m) | $35.22M | (m) | (m) |
| 2015-03-31 | (m) | $33.32M | (m) | (m) |
| 2014-12-31 | (m) | $31.11M | (m) | (m) |
| 2014-09-30 | (m) | $25.84M | (m) | (m) |
| 2014-06-30 | (m) | $10.30M | (m) | (m) |
| 2014-03-31 | (m) | $5.84M | (m) | (m) |
| 2013-12-31 | (m) | $2.75M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.90M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |